Halozyme Therapeutics (NASDAQ:HALO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $2.20 by 110.92 percent. This is a 119.05 percent decrease over earnings of $1.26 per share from the same period last year. The company reported quarterly sales of $451.767 million which beat the analyst consensus estimate of $437.977 million by 3.15 percent. This is a 51.60 percent increase over sales of $298.008 million the same period last year.